Andrew John Partridge, EVP & Chief Commercial Officer at Turning Point Therapeutics, Inc. (TPTX), sold 221 shares at $36.30 ($8K) on 2022-02-09, disclosed to the SEC on 2022-02-11.
Open-market sale of $8k TPTX by EVP & Chief Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |